FDA backs 3 psychedelic drug studies for mental illness

Ella Ruder / beckershospitalreview - The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The vouchers were issued to companies studying psilocybin for treatment-resistant depression and major depressive disorder as well…

AI Summary: The FDA announced a targeted push to accelerate clinical research into psychedelics for mental illness, issuing three commissioner vouchers to support rigorous trials of psychedelic therapies. The move aims to fast-track evidence generation under regulatory oversight, signalling growing agency willingness to explore unconventional treatments while keeping safety and trial standards squarely in view.

• FDA voucher push and federal policy shift (5)
• Psilocybin and brain science (4)
• Real-world use, safety and clinical readiness (3)
• All Other Stories

FDA voucher push and federal policy shift

Psilocybin and brain science

Real-world use, safety and clinical readiness

All Other Stories